Glenmark Pharmaceuticals Ltd approves Q2 FY27 results, reporting consolidated revenue of ₹4,247.3 crore and net profit of ₹263.8 crore
- Revenue rose 5.7% sequentially but fell 29.8% year-on-year; operating margin was approximately 20.3%.
- Net profit declined 45.4% sequentially and 56.8% year-on-year.
- Results include a ₹283.9 crore exceptional expense for a Humana settlement and related costs; auditors issued an unmodified limited-review conclusion.